吉西他滨和奥沙利铂，而非索拉非尼或紫杉醇，与钇-90联合使用时在降低肝癌和胆管癌细胞系活力方面具有协同作用。
Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.
作者信息
Edeline Julien, Coulouarn Cédric, Crouzet Laurence, Pracht Marc, Lepareur Nicolas, Clément Bruno, Garin Etienne
机构信息
Department of Medical Oncology, Centre Eugène Marquis, Av de la bataille Flandres Dunkerque, Rennes 35043, France; Inserm UMR991, Rennes, France.
Inserm UMR991, Rennes, France.
出版信息
J Vasc Interv Radiol. 2015 Dec;26(12):1874-78.e2. doi: 10.1016/j.jvir.2015.06.032.
Synergy between yttrium-90 (90Y) and antineoplastic drugs was investigated. Viability of HepaRG (hepatocellular carcinoma) and HuCCT1 (cholangiocarcinoma) cells was studied through a tetrazolium dye reduction assay. A combination index (CI) was calculated, with CI < 1 denoting synergy and CI > 1 denoting antagonism. In HepaRG cells, gemcitabine showed synergy with 90Y (CI = 0.70 [95% confidence interval = 0.65-0.75]), whereas oxaliplatin (CI = 1.15 [1.08-1.21]), paclitaxel (CI = 1.26 [1.15-1.37]), and sorafenib (CI = 1.77 [1.65-1.89]) showed antagonism. In HuCCT1 cells, gemcitabine (CI = 0.54 [0.50-0.58]) and oxaliplatin (CI = 0.86 [0.82-0.90]) showed synergy with 90Y, whereas paclitaxel (CI = 1.18 [1.09-1.27]) and sorafenib (CI = 1.21 [1.12-1.30]) showed antagonism. These results suggest that gemcitabine and oxaliplatin should be tested in combination with 90Y radioembolization for treatment of liver cancer.
研究了钇-90（90Y）与抗肿瘤药物之间的协同作用。通过四唑盐染料还原试验研究了HepaRG（肝细胞癌）和HuCCT1（胆管癌）细胞的活力。计算了联合指数（CI），CI<1表示协同作用，CI>1表示拮抗作用。在HepaRG细胞中，吉西他滨与90Y表现出协同作用（CI = 0.70[95%置信区间=0.65 - 0.75]），而奥沙利铂（CI = 1.15[1.08 - 1.21]）、紫杉醇（CI = 1.26[1.15 - 1.37]）和索拉非尼（CI = 1.77[1.65 - 1.89]）表现出拮抗作用。在HuCCT1细胞中，吉西他滨（CI = 0.54[0.50 - 0.58]）和奥沙利铂（CI = 0.86[0.82 - 0.90]）与90Y表现出协同作用，而紫杉醇（CI = 1.18[1.09 - 1.27]）和索拉非尼（CI = 1.21[1.12 - 1.30]）表现出拮抗作用。这些结果表明，应测试吉西他滨和奥沙利铂与90Y放射性栓塞联合用于治疗肝癌。
Zotero 插件